<DOC>
	<DOCNO>NCT01011959</DOCNO>
	<brief_summary>This randomize study safety tolerability multiple dos REGN88 rheumatoid arthritis patient receive treatment methotrexate .</brief_summary>
	<brief_title>A Multiple-dose Study Safety Tolerability REGN88 ( SAR153191 ) Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description>This multi-centered , randomize , double-blind , placebo-controlled , ascend parallel-group study safety tolerability REGN88 patient rheumatoid arthritis receiving concomitant methotrexate . This study conduct 3 part , include total 6 dose cohort . Part B begin safety Part A assess . Part C begin enrollment Part B complete .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients establish diagnosis Rheumatoid Arthritis Patients currently treat concomitant methotrexate least 12 week , stable dose least 6 week Persistent chronic current active infection Patients take anakinra within 2 week Patients take etanercept , cyclosporine , mycophenolate , tacrolimus , gold , penicillamine , sulfasalazine hydroxychloroquine within 4 week Patients take adalimumab within 6 week Patients take abatacept , azathioprine , cyclophosphamide infliximab within 12 week Patients take leflunomide rituximab within 6 month Patients prior treatment tocilizumab antiIL6 medication Significant arthritis medical condition could interfere study evaluation Participation clinical research study evaluate another investigational drug within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>